CSafe joins BioLife’s international associate community of chilly chain answer suppliers utilizing the evo® chilly chain administration platform
MONROE, Ohio and BOTHELL, Wash., Oct. 11, 2022 /PRNewswire/ — CSafe, one in every of the largest energetic and passive temperature-controlled transport solutions suppliers for prescription drugs, and BioLife Solutions, Inc. (NASDAQ: BLFS), a number one provider of class-defining bioproduction instruments and companies for the cell and gene therapy (“CGT”) and broader biopharma markets, introduced at present a brand new partnership to present a mixed international service community to help CGT merchandise, with a deal with enhanced reliability, safety and high quality.
CSafe joins BioLife’s international associate community of chilly chain answer suppliers serving the CGT market. BioLife expects to help 10,000-12,000 evo shipments of CGT beginning supplies and manufactured doses over the subsequent 12 months. The new partnership will present expanded supply chain choices for any CGT product, at any stage of growth, from early clinical-phase trials to international business scale.
CSafe will carry much more of its extremely dependable international attain to the CGT sector by means of this new alliance. Operating from 50+ service facilities worldwide, the firm is a confirmed, trusted associate for biopharmaceutical producers in search of to navigate supply chain complexity, with a monitor file that features transport solutions for six billion doses of a COVID-19 vaccine.
“CSafe is honored to partner with the team at BioLife Solutions, whose range of CGT bioproduction tools and services is peerless in the market. We are excited to merge these exceptional tools and services with our expertise in global, reliable scaled delivery,” mentioned CSafe CEO Patrick Schafer. “CGT is hitting its stride and needs global support. We know how important these therapies are to patients everywhere, and it’s our mission at CSafe to protect every shipment.”
“We’re excited to work with a global partner with a strong history of reliability and performance and a deep dedication to innovative therapies,” mentioned BioLife Solutions CEO Mike Rice. “We have the best LN2 technology and cGMP storage facilities in the market, in addition to our other world-class CGT solutions, and we are confident our collaboration with CSafe will extend our reach and result in even more reliability and real-time service for CGT partners.”
Media Contacts:
April Lynch
+1 937-245-6479
[email protected]
For BioLife Solutions:
At the Company
Troy Wichterman
Chief Financial Officer
(425) 402-1400
[email protected]
Investors
LHA Investor Relations
Jody Cain
(310) 691-7100
[email protected]
CSafe gives the most complete suite of thermal transport solutions for pharmaceutical chilly chain transport wants round the world. With a “patient-first” focus, deep {industry} experience and dedication to innovation, CSafe continues to ship industry-leading merchandise in each the energetic and passive segments. CSafe is the solely supplier with an end-to-end portfolio together with energetic and passive bulk air cargo, parcel, cell and gene and specialty last-mile use circumstances with the potential to meet the full vary of pharma cold-chain transport necessities with industry-leading high quality and reliability. Any dimension, any length and any temperature – CSafe is At the Heart of Your Cold Chain. csafeglobal.com
BioLife Solutions is a number one provider of class-defining bioproduction instruments and companies for the cell and gene therapy and broader biopharma markets. Our instruments portfolio contains our proprietary CryoStor® and HypoThermosol® biopreservation media for transport and storage, the ThawSTAR® household of automated, water-free thawing merchandise, evo® chilly chain administration system, high capacity cryogenic storage freezers, Stirling Ultracold mechanical freezers, SciSafe biologic storage companies, and Sexton Biotechnologies cell processing instruments. For extra data, please go to www.biolifesolutions.com, www.scisafe.com, www.stirlingultracold.com, or www.sextonbio.com and comply with BioLife on Twitter.
Caution Regarding Forward Looking Statements
Statements on this press launch that aren’t historic details are “forward-looking statements” that will contain materials dangers and uncertainties. The firm needs to warning readers not to place undue reliance on such forward-looking statements. All such statements converse solely as of the date made.
Photo – https://mma.prnewswire.com/media/1917780/BioLife_Solutions_DV10.jpg
Logo – https://mma.prnewswire.com/media/1917781/CSafe_Logomark_RGB_Logo.jpg
View authentic content material:https://www.prnewswire.co.uk/news-releases/csafe-and-biolife-solutions-inc-announce-partnership-to-expand-supply-chain-solutions-for-the-cell-and-gene-therapy-market-301645856.html
